- Home
- CE vs KRYS Comparison
CE vs KRYS Comparison
Compare CE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CE
- KRYS
- Stock Information
- Founded
- CE 1918
- KRYS 2015
- Country
- CE United States
- KRYS United States
- Employees
- CE N/A
- KRYS N/A
- Industry
- CE Major Chemicals
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CE Industrials
- KRYS Health Care
- Exchange
- CE Nasdaq
- KRYS Nasdaq
- Market Cap
- CE 4.5B
- KRYS 4.7B
- IPO Year
- CE 2005
- KRYS 2017
- Fundamental
- Price
- CE $38.70
- KRYS $206.67
- Analyst Decision
- CE Buy
- KRYS Strong Buy
- Analyst Count
- CE 18
- KRYS 9
- Target Price
- CE $57.33
- KRYS $214.22
- AVG Volume (30 Days)
- CE 2.4M
- KRYS 329.1K
- Earning Date
- CE 11-06-2025
- KRYS 11-03-2025
- Dividend Yield
- CE 0.31%
- KRYS N/A
- EPS Growth
- CE N/A
- KRYS 275.72
- EPS
- CE N/A
- KRYS 6.66
- Revenue
- CE $9,710,000,000.00
- KRYS $373,164,000.00
- Revenue This Year
- CE N/A
- KRYS $34.33
- Revenue Next Year
- CE $2.21
- KRYS $48.04
- P/E Ratio
- CE N/A
- KRYS $30.95
- Revenue Growth
- CE N/A
- KRYS 54.51
- 52 Week Low
- CE $35.48
- KRYS $122.80
- 52 Week High
- CE $77.43
- KRYS $212.98
- Technical
- Relative Strength Index (RSI)
- CE 44.71
- KRYS 68.58
- Support Level
- CE $35.48
- KRYS $192.52
- Resistance Level
- CE $42.76
- KRYS $209.96
- Average True Range (ATR)
- CE 1.93
- KRYS 8.52
- MACD
- CE 0.20
- KRYS 0.06
- Stochastic Oscillator
- CE 39.34
- KRYS 79.51
About CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.